Shareholder valueManagement needs to start thinking outside the box to bring existing shareholders more value. Doing a M&A at current share price would be a slap in the face. If management is so confident on being cash flow positive in the next 2 quarters and pending news with a pharma partner. I'd rather see them do a 10-1 reverse split, followed by a share buyback with the money from Tilray settlement. We could potentially be at at the same outstanding shares prior to the Vivo acquisition. I think that would be the best 1-2 punch we need to wake up this stock.